Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis to acquire TargeGen

Sanofi-aventis has signed an agreement to acquire US biopharma company, TargeGen, in a deal which could be worth up to $560m

Sanofi-aventis (S-A) has signed an agreement to acquire US biopharma company, TargeGen, in a deal which could be worth up to $560m. TargeGen develops small molecule kinase inhibitors to treat certain forms of leukaemia, lymphoma and other haematological malignancies and blood disorders.

Under the terms of the agreement, S-A will make an upfront payment of $75m, followed by further milestone payments as TargeGen lead product, TG101348, is developed. The transaction is expected to complete in Q3 of 2010.

"Sanofi-aventis brings many strengths to the continued development and potential commercialisation of TG101348," said Peter G Ulrich, president, CEO and co-founder of TargeGen. "With their global focus on oncology and long-term commitment to this patient population, we are confident they will maximise the potential of TG101348 across multiple clinical indications."

"The acquisition of TargeGen represents a further significant step to increase our engagement in the field of haematological malignancies," stated Dr Marc Cluzel, executive vice-president, research and development, at S-A. "In addition, this acquisition is another example of our strong commitment to oncology to provide patients, physicians and public health stakeholders with breakthrough medicines addressing unmet medical needs."

TG101348 is a potent inhibitor of Janus kinase 2 (JAK-2). It is an oral agent and is being developed for myeloproliferative diseases, including myelofibrosis (MF). MF is a chronic and progressive disorder in which there is a proliferation of certain cells of the bone marrow resulting in bone marrow fibrosis and it is associated with activating mutations of JAK-2. TG101348 has completed a multi-centre clinical phase I/II trial in patients with myelofibrosis and further studies are planned later this year.

Besides MF, TG101348 could be effective in other haematological malignancies, such as polycythemia vera (PV), a blood disorder in which the bone marrow produces too many red blood cells.

30th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics